NEWRON PHARMACEUT. EO-20 (NP5) - Net Assets
Based on the latest financial reports, NEWRON PHARMACEUT. EO-20 (NP5) has net assets worth €-11.13 Million EUR (≈ $-13.02 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€40.05 Million ≈ $46.83 Million USD) and total liabilities (€51.19 Million ≈ $59.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of NEWRON PHARMACEUT. EO-20 to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-11.13 Million |
| % of Total Assets | -27.8% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 156.08 |
NEWRON PHARMACEUT. EO-20 - Net Assets Trend (2021–2025)
This chart illustrates how NEWRON PHARMACEUT. EO-20's net assets have evolved over time, based on quarterly financial data. Also explore NEWRON PHARMACEUT. EO-20 (NP5) total assets for the complete picture of this company's asset base.
Annual Net Assets for NEWRON PHARMACEUT. EO-20 (2021–2025)
The table below shows the annual net assets of NEWRON PHARMACEUT. EO-20 from 2021 to 2025. For live valuation and market cap data, see NP5 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-11.13 Million ≈ $-13.02 Million |
-863.72% |
| 2024-12-31 | €1.46 Million ≈ $1.70 Million |
+104.87% |
| 2023-12-31 | €-29.91 Million ≈ $-34.97 Million |
-113.17% |
| 2022-12-31 | €-14.03 Million ≈ $-16.40 Million |
-551.56% |
| 2021-12-31 | €3.11 Million ≈ $3.63 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to NEWRON PHARMACEUT. EO-20's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 185100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €7.13 Million | % |
| Total Equity | €-11.13 Million | 100.00% |
NEWRON PHARMACEUT. EO-20 Competitors by Market Cap
The table below lists competitors of NEWRON PHARMACEUT. EO-20 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sword Group S.E
F:9RS
|
$316.28 Million |
|
Idun Industrier AB Series B
ST:IDUN-B
|
$316.47 Million |
|
Taiwan Optical Platform Co Ltd
TW:6464
|
$316.47 Million |
|
Regional Management Corp
NYSE:RM
|
$316.48 Million |
|
Zaggle Prepaid Ocean Services Limited
NSE:ZAGGLE
|
$316.14 Million |
|
Nalwa Sons Investments Limited
NSE:NSIL
|
$316.11 Million |
|
StealthGas Inc
F:S6W
|
$316.08 Million |
|
Sarana Meditama Metropolitan
JK:SAME
|
$315.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NEWRON PHARMACEUT. EO-20's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,458,000 to -11,135,000, a change of -12,593,000 (-863.7%).
- Net loss of 13,239,000 reduced equity.
- New share issuances of 350,000 increased equity.
- Other factors increased equity by 296,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-13.24 Million | -118.9% |
| Share Issuances | €350.00K | +3.14% |
| Other Changes | €296.00K | +2.66% |
| Total Change | €- | -863.72% |
Book Value vs Market Value Analysis
This analysis compares NEWRON PHARMACEUT. EO-20's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.17 | €15.30 | x |
| 2022-12-31 | €-0.79 | €15.30 | x |
| 2023-12-31 | €-1.68 | €15.30 | x |
| 2024-12-31 | €0.07 | €15.30 | x |
| 2025-12-31 | €-0.56 | €15.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NEWRON PHARMACEUT. EO-20 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -69.22%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (121.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -479.59% | -258.61% | 0.11x | 16.25x | €-15.21 Million |
| 2022 | 0.00% | -287.05% | 0.16x | 0.00x | €-16.09 Million |
| 2023 | 0.00% | -179.13% | 0.35x | 0.00x | €-13.23 Million |
| 2024 | 1086.63% | 30.83% | 0.80x | 43.83x | €15.70 Million |
| 2025 | 0.00% | -69.22% | 0.48x | 0.00x | €-12.13 Million |
Industry Comparison
This section compares NEWRON PHARMACEUT. EO-20's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,132,095,555
- Average return on equity (ROE) among peers: -68.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NEWRON PHARMACEUT. EO-20 (NP5) | €-11.13 Million | -479.59% | N/A | $316.25 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $242.58 Million | -85.63% | 0.52x | $204.16 Million |
| PreveCeutical Medical Inc (18H) | $-2.29 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.05 Billion | -15.51% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $1.82 Billion |
| BioNTech SE (22UA) | $19.22 Billion | -5.91% | 0.14x | $20.05 Billion |
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more